Literature DB >> 18160712

Doubling the size of the glucocorticoid receptor ligand binding pocket by deacylcortivazol.

Kelly Suino-Powell1, Yong Xu, Chenghai Zhang, Yong-Guang Tao, W David Tolbert, S Stoney Simons, H Eric Xu.   

Abstract

A common feature of nuclear receptor ligand binding domains (LBD) is a helical sandwich fold that nests a ligand binding pocket within the bottom half of the domain. Here we report that the ligand pocket of glucocorticoid receptor (GR) can be continuously extended into the top half of the LBD by binding to deacylcortivazol (DAC), an extremely potent glucocorticoid. It has been puzzling for decades why DAC, which contains a phenylpyrazole replacement at the conserved 3-ketone of steroid hormones that are normally required for activation of their cognate receptors, is a potent GR activator. The crystal structure of the GR LBD bound to DAC and the fourth LXXLL motif of steroid receptor coactivator 1 reveals that the GR ligand binding pocket is expanded to a size of 1,070 A(3), effectively doubling the size of the GR dexamethasone-binding pocket of 540 A(3) and yet leaving the structure of the coactivator binding site intact. DAC occupies only approximately 50% of the space of the pocket but makes intricate interactions with the receptor around the phenylpyrazole group that accounts for the high-affinity binding of DAC. The dramatic expansion of the DAC-binding pocket thus highlights the conformational adaptability of GR to ligand binding. The new structure also allows docking of various nonsteroidal ligands that cannot be fitted into the previous structures, thus providing a new rational template for drug discovery of steroidal and nonsteroidal glucocorticoids that can be specifically designed to reach the unoccupied space of the expanded pocket.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18160712      PMCID: PMC2268401          DOI: 10.1128/MCB.01541-07

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  36 in total

1.  Structural evidence for ligand specificity in the binding domain of the human androgen receptor. Implications for pathogenic gene mutations.

Authors:  P M Matias; P Donner; R Coelho; M Thomaz; C Peixoto; S Macedo; N Otto; S Joschko; P Scholz; A Wegg; S Bäsler; M Schäfer; U Egner; M A Carrondo
Journal:  J Biol Chem       Date:  2000-08-25       Impact factor: 5.157

Review 2.  Dissociated glucocorticoid receptor ligands.

Authors:  Heike Schäcke; Hartmut Rehwinkel
Journal:  Curr Opin Investig Drugs       Date:  2004-05

3.  Detection, delineation, measurement and display of cavities in macromolecular structures.

Authors:  G J Kleywegt; T A Jones
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  1994-03-01

4.  Cytotoxicity of cortivazol in childhood acute lymphoblastic leukemia.

Authors:  Jan Styczynski; Andrzej Kurylak; Mariusz Wysocki
Journal:  Anticancer Res       Date:  2005 May-Jun       Impact factor: 2.480

Review 5.  Conformational adaptation of nuclear receptor ligand binding domains to agonists: potential for novel approaches to ligand design.

Authors:  Marie Togashi; Sabine Borngraeber; Ben Sandler; Robert J Fletterick; Paul Webb; John D Baxter
Journal:  J Steroid Biochem Mol Biol       Date:  2005-02-19       Impact factor: 4.292

Review 6.  The search for safer glucocorticoid receptor ligands.

Authors:  Jonathan Rosen; Jeffrey N Miner
Journal:  Endocr Rev       Date:  2005-04-06       Impact factor: 19.871

7.  Atomic structure of progesterone complexed with its receptor.

Authors:  S P Williams; P B Sigler
Journal:  Nature       Date:  1998-05-28       Impact factor: 49.962

8.  Interactions of the phenylpyrazolo steroid cortivazol with glucocorticoid receptors in steroid-sensitive and -resistant human leukemic cells.

Authors:  E B Thompson; D Srivastava; B H Johnson
Journal:  Cancer Res       Date:  1989-04-15       Impact factor: 12.701

9.  Novel arylpyrazole compounds selectively modulate glucocorticoid receptor regulatory activity.

Authors:  Jen-Chywan Wang; Nilesh Shah; Carlos Pantoja; Sebastiaan H Meijsing; Joseph D Ho; Thomas S Scanlan; Keith R Yamamoto
Journal:  Genes Dev       Date:  2006-03-15       Impact factor: 11.361

10.  [3H]cortivazol: a unique high affinity ligand for the glucocorticoid receptor.

Authors:  J A Schlechte; S S Simons; D A Lewis; E B Thompson
Journal:  Endocrinology       Date:  1985-10       Impact factor: 4.736

View more
  39 in total

1.  Hormone binding and co-regulator binding to the glucocorticoid receptor are allosterically coupled.

Authors:  Samuel J Pfaff; Robert J Fletterick
Journal:  J Biol Chem       Date:  2010-03-24       Impact factor: 5.157

Review 2.  Structural and functional insights into nuclear receptor signaling.

Authors:  Lihua Jin; Yong Li
Journal:  Adv Drug Deliv Rev       Date:  2010-08-17       Impact factor: 15.470

3.  Ultrafast protein structure-based virtual screening with Panther.

Authors:  Sanna P Niinivehmas; Kari Salokas; Sakari Lätti; Hannu Raunio; Olli T Pentikäinen
Journal:  J Comput Aided Mol Des       Date:  2015-09-25       Impact factor: 3.686

4.  The nuclear receptor, Nor-1, markedly increases type II oxidative muscle fibers and resistance to fatigue.

Authors:  Michael A Pearen; Natalie A Eriksson; Rebecca L Fitzsimmons; Joel M Goode; Nick Martel; Sofianos Andrikopoulos; George E O Muscat
Journal:  Mol Endocrinol       Date:  2012-01-26

5.  Research resource: modulators of glucocorticoid receptor activity identified by a new high-throughput screening assay.

Authors:  John A Blackford; Kyle R Brimacombe; Edward J Dougherty; Madhumita Pradhan; Min Shen; Zhuyin Li; Douglas S Auld; Carson C Chow; Christopher P Austin; S Stoney Simons
Journal:  Mol Endocrinol       Date:  2014-05-21

6.  Thiazolidinediones are partial agonists for the glucocorticoid receptor.

Authors:  L Matthews; A Berry; M Tersigni; F D'Acquisto; A Ianaro; D Ray
Journal:  Endocrinology       Date:  2008-09-18       Impact factor: 4.736

7.  Structures and mechanism for the design of highly potent glucocorticoids.

Authors:  Yuanzheng He; Wei Yi; Kelly Suino-Powell; X Edward Zhou; W David Tolbert; Xiaobo Tang; Jing Yang; Huaiyu Yang; Jingjing Shi; Li Hou; Hualiang Jiang; Karsten Melcher; H Eric Xu
Journal:  Cell Res       Date:  2014-04-25       Impact factor: 25.617

8.  Optimization of drug-like properties of nonsteroidal glucocorticoid mimetics and identification of a clinical candidate.

Authors:  Christian Harcken; Doris Riether; Pingrong Liu; Hossein Razavi; Usha Patel; Thomas Lee; Todd Bosanac; Yancey Ward; Mark Ralph; Zhidong Chen; Donald Souza; Richard M Nelson; Alison Kukulka; Tazmeen N Fadra-Khan; Ljiljana Zuvela-Jelaska; Mita Patel; David S Thomson; Gerald H Nabozny
Journal:  ACS Med Chem Lett       Date:  2014-11-20       Impact factor: 4.345

9.  Deacylcortivazol-like pyrazole regioisomers reveal a more accommodating expanded binding pocket for the glucocorticoid receptor.

Authors:  Jessica A O Zimmerman; Mimi Fang; Bintou Doumbia; Alexis Neyman; Ji Hyeon Cha; Michael Thomas; Bonnie Hall; Meng Wu; Anne M Wilson; Miles A Pufall
Journal:  RSC Med Chem       Date:  2020-12-08

10.  Identification of SRC3/AIB1 as a preferred coactivator for hormone-activated androgen receptor.

Authors:  X Edward Zhou; Kelly M Suino-Powell; Jun Li; Yuanzheng He; Jeffrey P Mackeigan; Karsten Melcher; Eu-Leong Yong; H Eric Xu
Journal:  J Biol Chem       Date:  2010-01-19       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.